Stay updated on ARO-APOC3 in Dyslipidemia Clinical Trial
Sign up to get notified when there's something new on the ARO-APOC3 in Dyslipidemia Clinical Trial page.

Latest updates to the ARO-APOC3 in Dyslipidemia Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check44 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check51 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
- Check66 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
- Check73 days agoChange DetectedThe study has been updated to reflect a new open-label extension with a fixed dosing regimen of ARO-APOC3 every 3 months, while the number of study locations has decreased from 63 to 60.SummaryDifference4%
- Check102 days agoChange DetectedThe website has been updated from version v2.13.2 to v2.13.3.SummaryDifference0.1%
Stay in the know with updates to ARO-APOC3 in Dyslipidemia Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ARO-APOC3 in Dyslipidemia Clinical Trial page.